Optimal Dosage of Ticagrelor in Korean Patients With AMI
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
East Asian patients will be required optimal dose of newer P2Y12 inhibitor (ticagrelor) to
determine the safer treatment and better outcome. Whether low dose of ticagrelorI is more
adequate for clinical practice in Korea is unclear. Therefore, the investigators aim to
evaluate efficacy and safety of low dose of ticagrelor in Acute Myocardial Infarction (AMI)
undergoing percutaneous coronary intervention(PCI).